Status:

COMPLETED

Heart EXPAND Continued Access Protocol

Lead Sponsor:

TransMedics

Conditions:

Heart Transplant

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The OCS™ Heart System will be used to preserve and assess donor hearts that do not meet current standard donor heart acceptance criteria for transplantation in this continued access protocol.

Detailed Description

To provide additional data evaluating the safety and effectiveness of the OCS™ Heart System to preserve and assess donor hearts that do not meet current standard donor heart acceptance criteria (as id...

Eligibility Criteria

Inclusion

  • Inclusion Criteria (DONOR):
  • At least one of the following:
  • Expected total cross-clamp time of ≥ 4 hours
  • Expected total cross-clamp time of ≥ 2 hours PLUS one or more of the following risk factors Donor age 45-55 years, inclusive, with no coronary catheterization data; or Donor age ≥ 55 years; or Left ventricular septal or posterior wall thickness of \>12 mm, but ≤ 16 mm; or Reported down time of ≥ 20 min, with stable hemodynamics at time of final assessment; or Left heart ejection fraction (EF) ≥ 40%, but ≤ 50% at time of acceptance of offer; or Donor angiogram with luminal irregularities with no significant CAD (≤ 50%); or History of carbon monoxide poisoning with good cardiac function at time of donor assessment; or Social history of alcoholism with good cardiac function at time of donor assessment; or History of diabetes without significant CAD (≤ 50%) on angiogram.
  • Exclusion
  • CAD with \> 50% stenosis on angiogram, or
  • Cardiogenic shock or myocardial infarction, or
  • EF consistently \< 40%, or
  • Significant valve disease except for competent bicuspid aortic valve.
  • Eligibility Criteria (RECIPIENT)
  • Registered primary heart transplant candidate
  • Age \>18 years old
  • Written informed consent. Exclusion
  • Prior solid organ or bone marrow transplant
  • Chronic use of hemodialysis or renal replacement therapy for diagnosis of chronic renal insufficiency requiring dialysis
  • Multi-organ transplant.

Exclusion

    Key Trial Info

    Start Date :

    April 17 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 12 2022

    Estimated Enrollment :

    75 Patients enrolled

    Trial Details

    Trial ID

    NCT03835754

    Start Date

    April 17 2019

    End Date

    August 12 2022

    Last Update

    January 17 2025

    Active Locations (12)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (12 locations)

    1

    Cedars-Sinai

    Los Angeles, California, United States, 90211

    2

    Stanford University

    Palo Alto, California, United States, 94304

    3

    Yale New Haven Hospital

    New Haven, Connecticut, United States, 06510

    4

    AdventHealth Orlando

    Orlando, Florida, United States, 32803